Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.75 |
| ▸ | HMGCR | P04035 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | SLC13A5 | Q86YT5 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CPT2 | P23786 | 2/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL5874391 | 0.90 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL31518964 | 0.90 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL3454436 | 0.90 | ALDH1A1 (0.83) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL31538120 | 0.89 | ALDH1A1 (0.65) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL17099621 | 0.87 | ALDH1A1 (0.79) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL7155667 | 0.87 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1243198 | 0.87 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL6838001 | 0.87 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL15660063 | 0.87 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A | |
| Citric Acid SCHEMBL1243199 | 0.87 | ALDH1A1 (0.88) | ALDH1A1HMGCRCHRM1TBXA2RADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9675546-B2 | Method of treating atrophic vaginitis | KLAMERUS BERNADETTE (US) | 2017-06-13 | — | — | US | claimed |
| EP-2034984-A2 | METHOD OF TREATING ATROPHIC VAGINITIS | Pear Tree Women's Health Care (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2007143607-A2 | METHOD OF TREATING ATROPHIC VAGINITIS | PEAR TREE WOMEN'S HEALTH CARE (US) | 2007-12-13 | — | — | WO | claimed |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
| CN-110291200-B | Agent ligand induction of transgene expression in mammalian cells | 西雅图儿童医院（DBA西雅图儿童研究所） | 2024-05-14 | — | — | CN | disclosed |
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CATALENT PHARMA SOLUTIONS, LLC | 2024-05-09 | — | — | US | disclosed |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | MEKANISTIC THERAPEUTICS, LLC | 2024-03-14 | — | — | US | disclosed |
| WO-2024049734-A1 | IMPLANTABLE DEVICE FOR INTRATUMORALLY ADMINISTERING A THERAPEUTIC AGENT | CELANESE EVA PERFORMANCE POLYMERS LLC (US) | 2024-03-07 | — | — | WO | disclosed |
| US-20240050415-A1 | DACLATASVIR FOR USE IN TREATING LUNG AND PROSTATE CANCER | HENRY FORD HEALTH SYSTEM (US) | 2024-02-15 | — | — | US | disclosed |
| US-11879009-B2 | Multifunctional protein molecules comprising decorin and use thereof | CATALENT PHARMA SOLUTIONS, LLC (US) | 2024-01-23 | — | — | US | disclosed |
| EP-3439640-B1 | NANOPARTICLES FOR DRUG DELIVERY TO TREAT BONE DISEASE | CLEVELAND CLINIC FOUND (US) | 2024-01-17 | — | — | EP | disclosed |
| US-20040142973-A1 | Method of treatment of prostate cancer and composition for treatment thereof | CASTLE ERIK P (US) | 2004-07-22 | — | — | US | disclosed |
| EP-1436423-A2 | GENETIC ANALYSIS FOR STRATIFICATION OF CANCER RISK | Intergenetics Incorporated (US) | 2004-07-14 | — | — | EP | disclosed |
| US-20040002071-A1 | Genetic analysis for stratification of cancer risk | INTERGENETICS, INC. | 2004-01-01 | — | — | US | disclosed |
| WO-2003045309-A2 | Peptides, peptide compositions,and methods of use in binding p 185 | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2003025141-A2 | GENETIC ANALYSIS FOR STRATIFICATION OF CANCER RISK | INTERGENETICS INCORPORATED (US) | 2003-03-27 | — | — | WO | disclosed |
| EP-1289519-A1 | METHODS OF TREATING ANDROGEN DEFICIENCY IN MEN USING SELECTIVE ANTIESTROGENS | Fisch, Harry (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6391920-B1 | Methods of treating androgen deficiency in men using selective antiestrogens | ASPEN PARK PHARMACEUTICALS, INC. | 2002-05-21 | — | — | US | disclosed |
| WO-2001091744-A1 | METHODS OF TREATING ANDROGEN DEFICIENCY IN MEN USING SELECTIVE ANTIESTROGENS | FISCH HARRY (US) | 2001-12-06 | — | — | WO | disclosed |
| US-5470883-A | Antiestrogen | STROMBERG BRENT V (US) | 1995-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150452-A1 | MULTIFUNCTIONAL PROTEIN MOLECULES COMPRISING DECORIN AND USE THEREOF | CD2BP2, DSTN, SDCBP | MEN1 1307/4885ALDH1A1 3337/4885HMGCR 4652/4885 |
| US-11879009-B2 | Multifunctional protein molecules comprising decorin and use thereof | CD2BP2, DSTN, SDCBP | MEN1 1307/4885ALDH1A1 3337/4885HMGCR 4652/4885 |
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | MEN1 1831/4885ALDH1A1 4447/4885HMGCR 3808/4885 |
| US-20240083868-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | MEN1 1831/4885ALDH1A1 4447/4885HMGCR 3808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.